Epidermal Growth Factor Receptor (EGFR) T790M Mutation Identified in Plasma Indicates Failure Sites and Predicts Clinical Prognosis in Non-Small Cell Lung Cancer Progression During First-Generation Tyrosine Kinase Inhibitor Therapy: a Prospective Observational Study

Plasma circulating tumor DNA (ctDNA) is an ideal approach to detecting the epidermal growth factor receptor (EGFR) T790M mutation, which is a major mechanism of resistance to first-generation EGFR-tyrosine kinase inhibitor (TKI) therapy. The present study aimed to explore the association of ctDNA-identified T790M mutation with disease failure sites and clinical prognosis in non-small cell lung cancer (NSCLC) patients.